Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

A phase IV trial of Shingrix on incident dementia diagnosis in adults aged ≥76 years in Finland Recruiting

2025-524598-17-00 Incident dementia 6 2026-03-31
PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity_PHACYLOB. Recruiting

2024-519461-22-00 Attention Deficit Disorder with or without Hyperactivit 6 2026-03-30
TRITON-PN: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin Amyloidosis with Poly… Recruiting

2025-522544-40-00 Hereditary transthyretin-mediated amyloidosis with poly 5 2026-03-27
Zanubritnib and anti-MAG neuropathy Recruiting

2025-523091-23-00 Peripheral anti-MAG neuropathy, waldenstrom macroglobul 4 2026-03-24
A clinical trial of MK-6916 in healthy participants (MK-6916-010) Recruiting

2025-524570-41-00 Acute and Chronic pain 3 2026-03-16
A Long-term Extension Study of ORX750 in Participants with Narcolepsy and Idiopathic Hypersomnia Recruiting

2025-522987-34-00 Narcolepsy and Idiopathic Hypersomnia 4 2026-03-13
Guttmann NeuroRecovery – Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous s… Recruiting

2025-521877-14-00 Traumatic spinal cord injury 9 2026-03-11
Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patient… Recruiting

2024-519770-38-00 Migraine 6 2026-03-05
An Open-Label Extension, Multi-Centered, Phase 2 Trial of TEV-56286 (Emrusolmin) for Multiple System Atrophy Recruiting

2025-521642-14-00 Multiple System Atrophy 4 2026-03-05
A Phase 2 study to assess the safety and efficacy of SUL-238 in patients with early, untreated Parkinson’s Disease Recruiting

2025-524674-42-00 Parkinson’s Disease 4 2026-03-05
A trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis Recruiting

2025-522922-11-00 Progressive multiple sclerosis (MS) 4 2026-03-03
A study of the safety, tolerability, pharmacokinetics and preliminary efficacy of TNV108 in healthy adults and patients with diabetic periph… Recruiting

2025-524258-32-00 Diabetic Peripheral Neuropathy (DPN) 1 2026-03-02
Early-stage clinical trial investigating the individual and combined effect of two drugs, senicapoc and perampanel, as part of the treatment… Recruiting

2025-522605-37-00 Glioblastoma 3 2026-03-01
A Safety and Efficacy Study of GTX-102 in Subjects with Deletion- or Nondeletion-type Angelman Syndrome (Aurora) Recruiting

2024-519393-39-00 Angelman Syndrome 4 2026-02-27
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting

2024-516411-24-00 Insomnia Disorder 5 2026-02-25
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Recruiting

2024-511101-28-00 Episodic Migraine Chronic Migraine 4 2026-02-24
A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults. Recruiting

2025-522652-58-01 Narcolepsy 1 2026-02-19
A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in par… Recruiting

2024-513927-18-00 Amyotrophic Lateral Sclerosis 4 2026-02-16
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx with Low-Dose Albumin Administration (MOZEG) Recruiting

2023-509261-20-00 Ischemic stroke 4 2026-02-09
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD) Recruiting

2024-517413-33-00 Idiopathic Parkinson's Disease 4 2026-02-03
A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants Recruiting

2025-524310-28-00 Epilepsy, amotrophic lateral sclerosis, neuropathy 3 2026-02-02
Biomarkers of the locus coeruleus nucleus: links with early tau pathology, cognition and AD risk. LocusTau Recruiting

2023-507668-38-00 Alzheimer’s Disease 4 2026-02-02